Patents Assigned to Rohto Pharmaceutical Co., Ltd.
  • Patent number: 9034931
    Abstract: This invention relates to an aqueous ophthalmic composition comprising (A) polyoxyethylene castor oil in which the average number of moles of added ethylene oxide is 2 to 12 and (B) terpenoid. According to the present invention, an aqueous ophthalmic composition having an improved foam disappearance speed can be obtained.
    Type: Grant
    Filed: December 27, 2011
    Date of Patent: May 19, 2015
    Assignee: ROHTO PHARMACEUTICAL CO., LTD.
    Inventors: Chinatsu Furumiya, Takayuki Miyano, Atsuko Nakata, Eri Matsumoto
  • Publication number: 20150064281
    Abstract: The present invention provides an ophthalmic composition containing (A) a biguanide-based disinfectant and (B) zinc chloride. According to the present invention, an ophthalmic composition having remarkably increased disinfection effects against Acanthamoeba is provided.
    Type: Application
    Filed: April 4, 2013
    Publication date: March 5, 2015
    Applicant: ROHTO PHARMACEUTICAL CO., LTD.
    Inventors: Kazuhiro Fukushima, Mariyo Kato, Yoshihiro Takai, Masashi Itoh
  • Publication number: 20150018416
    Abstract: The present invention relates to an aqueous ophthalmic composition comprising (A) polyoxyethylene castor oil, (B) polyethylene glycol monostearate, and (C) at least one member selected from the group consisting of sesame oil, castor oil, vitamin A, and chlorobutanol.
    Type: Application
    Filed: November 29, 2013
    Publication date: January 15, 2015
    Applicant: ROHTO PHARMACEUTICAL CO., LTD.
    Inventors: Ryo Komurasaki, Yoko Mizutare, Atsuko Nakata
  • Publication number: 20140302146
    Abstract: The present invention provides an ophthalmic aqueous composition having an oil-in-water emulsion including a vegetable oil, a non-ionic surfactant, and a terpenoid, wherein an average particle diameter of emulsion particles is within the range of 30 nm to 300 nm.
    Type: Application
    Filed: July 5, 2012
    Publication date: October 9, 2014
    Applicant: ROHTO PHARMACEUTICAL CO.,LTD.
    Inventors: Takahiro Kurose, Takayuki Miyano, Toru Okubo, Mariyo Kato
  • Publication number: 20140243419
    Abstract: Application of a pharmaceutical preparation comprising geranylgeranylacetone to the mucosa of, for example, the eye, nose, oral cavity or pharynx can efficiently prevent, ameliorate or treat retinal diseases such as glaucoma, retinitis pigmentosa, age-related macular degeneration, and diabetic retinopathy.
    Type: Application
    Filed: May 1, 2014
    Publication date: August 28, 2014
    Applicant: ROHTO PHARMACEUTICAL CO., LTD.
    Inventors: Takahiro KUROSE, Yoshihiro TAKAI, Takayuki MIYANO, Yusuke TAKEUCHI
  • Patent number: 8754029
    Abstract: The present invention provides an ophthalmic composition which stabilizes the tear film during wearing contact lens, prevents eye dryness, imparts a favorable sensation in using, is highly convenient with no risk of misuse and shows a high efficiency in the course from manufacturing to sales. More specifically, the present invention provides a wetting solution—eye drops for contact lenses comprising (A) one or more member(s) selected from the group consisting of a cellulose-based polymer, a vinyl-based polymer, polyethylene glycol and dextran; and (B) a terpenoid.
    Type: Grant
    Filed: November 15, 2012
    Date of Patent: June 17, 2014
    Assignee: Rohto Pharmaceutical Co., Ltd.
    Inventors: Yasuko Matsumura, Kazuhiro Fukushima
  • Patent number: 8727651
    Abstract: An elevating container includes an elliptically shaped main tube, a non-circularly shaped moveable support unit which moves upwardly or downwardly along an inner surface of a storage tube of the main tube without rotating, and a driving unit fitted to the main tube to rotate in threaded engagement to the support unit without moving upwardly or downwardly. A seal section at the lower end of the inner peripheral surface of the storage tube and a sealing cylinder at the lower end of the support unit are air-tightly fitted to each other. In addition, positioning ribs are provided at the lower end of the storage tube, and positioning notches are provided at the lower end of the moveable support unit. When the positioning ribs and the positioning notches are engaged with each other, a circumferential misalignment between the main tube and the support unit is corrected.
    Type: Grant
    Filed: February 3, 2009
    Date of Patent: May 20, 2014
    Assignees: Rohto Pharmaceutical Co., Ltd., Yoshino Kogyosho Co., Ltd
    Inventors: Ken Arai, Takamitsu Okawara, Masakazu Mameta, Tsutomu Kobayashi, Hideo Uemura
  • Publication number: 20140128475
    Abstract: A prophylactic, ameliorating or therapeutic agent for a retinal disease, the agent comprising geranylgeranylacetone which (a) is a mixture of (5E,9E,13E)-geranylgeranylacetone and (5Z,9E,13E)-geranylgeranylacetone, the (5E,9E,13E)-geranylgeranylacetone content of the mixture being 80% by weight or more, (b) consists of (5E,9E,13E)-geranylgeranylacetone, or (c) consists of (5Z,9E,13E)-geranylgeranylacetone directly suppresses the death of a retinal cell, thereby fundamentally preventing, ameliorating or treating the retinal disease.
    Type: Application
    Filed: January 14, 2014
    Publication date: May 8, 2014
    Applicant: ROHTO PHARMACEUTICAL CO., LTD.
    Inventors: Takahiro KUROSE, Takayuki MIYANO, Mariyo KATO, Yoshihiro TAKAI
  • Patent number: 8669241
    Abstract: The ophthalmic composition of the invention comprises (A) lecithin and (B) at least one refrigerant selected from the group consisting of camphor, borneol, eucalyptus oil, and bergamot oil. In the ophthalmic composition, the odor of lecithin is efficiently masked by the refrigerant. The odor of lecithin after aging is also masked by the refrigerant. Since the refrigerant is volatile, the concentration thereof in a composition tends to gradually decrease. It is surprising that the odor of lecithin after aging can nevertheless be masked.
    Type: Grant
    Filed: December 1, 2009
    Date of Patent: March 11, 2014
    Assignee: Rohto Pharmaceutical Co., Ltd.
    Inventors: Yasuko Matsumura, Mariyo Kato
  • Publication number: 20140045948
    Abstract: An ophthalmic composition kit comprising an ophthalmic container holding an ophthalmic composition comprising geranylgeranylacetone, the ophthalmic container having a surface in contact with the ophthalmic composition, the surface being at least partially or wholly made of a container material selected from the group consisting of a polyolefin, an acrylic acid resin, a terephthalic acid ester, a polycarbonate, a polymethylterpene, a fluorine resin and a glass, the ophthalmic composition kit having an advantage that the loss of the geranylgeranylacetone content or decrease in the geranylgeranylacetone concentration in the ophthalmic composition is very little.
    Type: Application
    Filed: October 17, 2013
    Publication date: February 13, 2014
    Applicant: ROHTO PHARMACEUTICAL CO., LTD.
    Inventors: Takayuki MIYANO, Takahiro KUROSE
  • Publication number: 20140005277
    Abstract: This invention relates to an aqueous ophthalmic composition comprising (A) polyoxyethylene castor oil and (B) sesame oil. According to the aqueous ophthalmic composition of the present invention, defoaming time is reduced, preservative efficacy is enhanced and photostability is improved.
    Type: Application
    Filed: December 19, 2012
    Publication date: January 2, 2014
    Applicant: ROHTO PHARMACEUTICAL CO., LTD.
    Inventors: Atsuko NAKATA, Eri MATSUMOTO
  • Publication number: 20140005274
    Abstract: This invention relates to an aqueous ophthalmic composition comprising (A) polyoxyethylene castor oil in which the number of moles of added ethylene oxide is 2 to 30, and (B) at least one member selected from the group consisting of castor oil and vitamin A. According to the aqueous ophthalmic composition of the present invention, the defoaming time can be reduced even when foam is generated by vibration or impact.
    Type: Application
    Filed: December 19, 2012
    Publication date: January 2, 2014
    Applicant: ROHTO PHARMACEUTICAL CO., LTD.
    Inventor: Atsuko NAKATA
  • Publication number: 20130331458
    Abstract: An ophthalmic composition kit comprising an ophthalmic container holding an ophthalmic composition comprising geranylgeranylacetone, the ophthalmic container having a surface in contact with the ophthalmic composition, the surface being at least partially or wholly made of a container material selected from the group consisting of a polyolefin, an acrylic acid resin, a terephthalic acid ester, a polycarbonate, a polymethylterpene, a fluorine resin and a glass, the ophthalmic composition kit having an advantage that the loss of the geranylgeranylacetone content or decrease in the geranylgeranylacetone concentration in the ophthalmic composition is very little.
    Type: Application
    Filed: February 25, 2013
    Publication date: December 12, 2013
    Applicant: ROHTO PHARMACEUTICAL CO., LTD.
    Inventor: ROHTO PHARMACEUTICAL CO., LTD.
  • Publication number: 20130296446
    Abstract: This invention relates to an aqueous ophthalmic composition comprising (A) polyoxyethylene castor oil in which the average number of moles of added ethylene oxide is 2 to 12 and (B) terpenoid. According to the present invention, an aqueous ophthalmic composition having an improved foam disappearance speed can be obtained.
    Type: Application
    Filed: December 27, 2011
    Publication date: November 7, 2013
    Applicant: ROHTO PHARMACEUTICAL CO., LTD.
    Inventors: Chinatsu Furumiya, Takayuki Miyano, Atsuko Nakata, Eri Matsumoto
  • Publication number: 20130274332
    Abstract: An object of the present invention is to provide an ophthalmic composition for contact lens that can inhibit bacterial adhesion to a contact lens. The ophthalmic composition for contact lens can be prepared by using a combination of (A) polyoxyethylene castor oil and (B) terpenoid.
    Type: Application
    Filed: December 15, 2011
    Publication date: October 17, 2013
    Applicant: ROHTO PHARMACEUTICAL CO., LTD.
    Inventors: Chinatsu Furumiya, Atsuko Nakata
  • Publication number: 20130244978
    Abstract: The present invention provides an ophthalmic composition which stabilizes the tear film during wearing contact lens, prevents eye dryness, imparts a favorable sensation in using, is highly convenient with no risk of misuse and shows a high efficiency in the course from manufacturing to sales. More specifically, the present invention provides a wetting solution—eye drops for contact lenses or an ophthalmic composition/solution for contact lenses, which comprises (A) one or more member(s) selected from the group consisting of a cellulose-based polymer, a vinyl-based polymer, polyethylene glycol and dextran; and (B) a terpenoid.
    Type: Application
    Filed: May 8, 2013
    Publication date: September 19, 2013
    Applicant: ROHTO PHARMACEUTICAL CO., LTD.
    Inventors: Yasuko MATSUMURA, Kazuhiro FUKUSHIMA
  • Publication number: 20130210921
    Abstract: A method for giving warmth to skin, wherein an external composition for skin is provided, which gives good warmth without inducing irritation or pain and whose sustainability of warmth is good. The external composition for skin contains (A) an agent for giving warmth and (B) at least one member selected from the group consisting of fatty acid esters of aliphatic polyhydric alcohols and aromatic carboxylic acid esters of lower alcohols or aliphatic polyhydric alcohols.
    Type: Application
    Filed: February 14, 2013
    Publication date: August 15, 2013
    Applicant: ROHTO PHARMACEUTICAL CO., LTD.
    Inventor: ROHTO PHARMACEUTICAL CO., LTD.
  • Patent number: 8501822
    Abstract: An ophthalmic composition that, despite containing alginic acid and/or a salt thereof, has improved tackiness during use and provides a satisfactory use feeling. The composition has an improved ability to remain on the eye mucosa. The ophthalmic composition contains (A) alginic acid and/or a salt thereof in combination with (B) hyaluronic acid and/or a salt thereof.
    Type: Grant
    Filed: March 27, 2012
    Date of Patent: August 6, 2013
    Assignee: Rohto Pharmaceutical Co., Ltd.
    Inventors: Eri Matsumoto, Yasuko Nishina, Kenichi Haruna, Harumasa Arita, Akiko Kita
  • Publication number: 20130102977
    Abstract: The present invention provides an ophthalmic composition which stabilizes the tear film during wearing contact lens, prevents eye dryness, imparts a favorable sensation in using, is highly convenient with no risk of misuse and shows a high efficiency in the course from manufacturing to sales. More specifically, the present invention provides a wetting solution—eye drops for contact lenses comprising (A) one or more member(s) selected from the group consisting of a cellulose-based polymer, a vinyl-based polymer, polyethylene glycol and dextran; and (B) a terpenoid.
    Type: Application
    Filed: November 15, 2012
    Publication date: April 25, 2013
    Applicant: ROHTO PHARMACEUTICAL CO., LTD.
    Inventor: ROHTO PHARMACEUTICAL CO., LTD.
  • Publication number: 20120238519
    Abstract: An ophthalmic composition that, despite containing alginic acid and/or a salt thereof, has improved tackiness during use and provides a satisfactory use feeling. The composition has an improved ability to remain on the eye mucosa. The ophthalmic composition contains (A) alginic acid and/or a salt thereof in combination with (B) hyaluronic acid and/or a salt thereof.
    Type: Application
    Filed: March 27, 2012
    Publication date: September 20, 2012
    Applicant: ROHTO PHARMACEUTICAL CO., LTD.
    Inventors: Eri MATSUMOTO, Yasuko NISHINA, Kenichi HARUNA, Harumasa ARITA, Akiko KITA